Fluticasone Propionate Nasal Spray (FLONASE(R)) will be the first product marketed under this arrangement
MASON, Ohio, March 11 /PRNewswire/ -- Prasco Laboratories, announced today it has entered into a marketing and distribution agreement with GlaxoSmithKline (NYSE: GSK). FLONASE(R) (fluticasone propionate) Nasal Spray is the first product to be marketed under this agreement. Prasco, as GSK's agent and on GSK's behalf, will solicit orders for, and distribute Fluticasone Propionate Nasal Spray to all trade classes in the U.S. under a GSK/Prasco label.
(Photo: http://www.newscom.com/cgi-bin/prnh/20090311/CL81889)
"We are especially proud to have established this relationship with GlaxoSmithKline, a global leader in the research-based pharmaceutical industry," said Prasco Chief Executive Officer E. Thomas Arington. "We look forward to working with GSK to provide more choices for patients in the generics market."
"GlaxoSmithKline is always looking for opportunities to increase access to our medicines for patients," said Stan Hull, GlaxoSmithKline Senior Vice President, U.S. Pharmaceuticals. "The arrangement with Prasco, a known leader in the generics market, allows GSK to expand participation in the generic market in a new way."
Fluticasone Propionate Nasal Spray is AB-rated, therapeutically equivalent and substitutable for the brand FLONASE Nasal Spray. Fluticasone Propionate is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older.
FLONASE(R) is a registered trademark of Glaxo Group Limited, UK.
About Prasco
Prasco's mission i
'/>"/>
| SOURCE Prasco Laboratories Copyright©2009 PR Newswire. All rights reserved |